Currently, women with breast cancer are eligible for HER2/neu (HER2) based therapy if their tumors express the HER2 protein, as determined by immunohistochemistry (IHC) staining, or if their tumors demonstrate her2/neu gene amplification, as determined by fluorescence in situ histochemistry (FISH). The gene discussed is ERBB2; the disease is breast cancer.